fentanyl | CARLAT PUBLISHING

Note From the Editor-in-Chief

July 1, 2024

Joshua D. Feder, MD.

Dr. Feder remains alarmed: right now, it’s about heat, social media, and fentanyl - hear his direct advice and protect your patients and yourselves from the current ravages of our times.

Note From the Editor-in-Chief

November 1, 2023

Joshua D. Feder, MD

Joshua D. Feder, MD.

Can prescribers do cognitive behavioral therapy for obsessive compulsive disorder (OCD)? How do you treat OCD when it’s mixed with other conditions? What to tell families asking for invasive Deep Brain Stimulation for OCD? How can we minimize the problems of antipsychotics? And what about lithium – should you use it more? Join us and learn!

Expert Q&A

The State of Opioids on the Street

May 29, 2023

Daniel Ciccarone, MD, MPH

Daniel Ciccarone, MD, MPH.

Justine Miner Professor of Addiction Medicine at the University of California San Francisco.

Dr. Ciccarone is a member of the scientific advisory board for Celero Systems. Relevant financial relationships listed for the author have been mitigated.

Dr. Ciccarone sheds light on the current chaotic and perilous situation surrounding illicit opioids found on the streets.

Expert Q&A

Interpreting Urine Drug Tests

April 1, 2023

Karen Moeller, PharmD

Karen Moeller, PharmD. Clinical professor, Department of Pharmacy Practice, University of Kansas School of Pharmacy. Lawrence, KS. Board-certified psychiatric pharmacist, inpatient psychiatry unit, University of Kansas Health Systems. Kansas City, KS.

Dr. Moeller has no financial relationships with companies related to this material.

Drug screen accuracy depends on several factors, including the type of lab test, the number of hours since the patient’s use of the drug, and more.. Dr. Moeller reviews key points.

Drug Overdoses in the US: Trends and Prevention Strategies

November 5, 2021

Joshua Sharfstein, MD

Joshua Sharfstein, MD

Professor of the Practice of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Dr. Sharfstein has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Increases in drug overdose mortality continues unabated around the country driven by widespread availability of illicit fentanyl and methamphetamines. Dr. Sharfstein provides context to these concerning trends and discusses prevention and harm reduction strategies clinicians can implement for their patients.

A New Buprenorphine Dosing Strategy for Easier Induction From Fentanyl

November 5, 2021

Oluwole Jegede, MD, PhD

Oluwole Jegede, MD. Dr. Jegede has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Avoiding buprenorphine induced withdrawal during induction can be particularly tricky for those using fentanyl. Researchers describe a novel induction dosing strategy that mitigates this risk.